Commercial Engagements

Solution 5

Turning Science into Global Value

Building a global success story requires more than strong R&D, clinical excellence, and medical leadership. subrosa’s Commercial Engagement teams provide the structure, strategy, and operational precision biopharma companies need to launch smarter, scale faster, and create measurable impact across the full product lifecycle — from value creation to value realization.

We integrate the knowledge and insights of our clinical, medical, regulatory, market access, and commercial units to strengthen the most critical commercialization workstreams: validating real market size, identifying patients early in Rare Disease indications, and shaping global go-to-market and local market access strategies.

With global networks and true local reach, subrosa connects capital, commercial strategy, and execution. This allows us to rapidly design and deliver flexible, tailored solutions — from deployed HCP-promotion teams (field, remote, or hybrid) to omnichannel customer contact centers and patient support & adherence programs — ensuring that scientific evidence translates into patient benefit and sustained value creation.

Our long-lasting relationships and access to Executives and Talent help us acquire the individuals you need to succeed across the commercial journey — permanent, ad interim (“xperiods”), or contracted.

Our Capital teams complement this by selecting co-development, licensing, or distribution partners; advising CFOs; and supporting fundraising, grants, and exit pathways to maximize reach, control, and value realization.

Commercial Engagements

Our Integrated Commercial Solutions

subrosa 01

Commercial Consulting

Commercial Excellence Across Lifecycles

Commercial Consulting

subrosa’s Commercial Consulting teams provide the commercial structure, strategy, and operational precision biopharma companies need to launch smarter, scale faster, and operate with confidence — making impact across the full product lifecycle: launch, growth, maturity, and loss of exclusivity. We bring deep scientific knowledge, experience, and global infrastructure together to support key critical commercial workstreams: optimize regulatory, market access, medical & commercial structures, design omnichannel strategies and hybrid sales teams, targeting, sales-force sizing, etc.

subrosa OmicsAI 02

Early Patient Identification (Post-Launch)

Illuminate the Unseen

Early Patient Identification (Post-Launch)

subrosa OmicsAI’s unique clinical patient identification programs are built on our proprietary global repositories of rare disease patients — genetically confirmed. “Unseen” patients, far beyond the excellence centers, are detected years earlier than today’s standards, hitting a precisely calculated success rate. Not estimated — data-driven, calculated. Proven in more than 40 programs worldwide. Published. Furthermore, 42health finds patients through awareness programs with HCPs.

subrosa OmicsAI 03

Rare Disease Market Size Validation

Massive Gap Between Assumed and Real Prevalence

Rare Disease Market Size Validation

Understanding the true prevalence of diseases is fundamental to underpin orphan drug designation, etc. But nearly all Rare Disease patient identification studies & analyses show that prevalence ends up being always severely understated. This is exactly where subrosa adds value. subrosa OmicsAI can evaluate, validate, and publish the real prevalence, incidence, and market size for nearly any genetically driven Rare Disease. Early patient identification programs begin best before or in parallel with CRO activities to ensure more eligible patients for time-sensitive trials and to generate realistic epidemiological data for orphan designation, health economic models, and capital market communication.

axxessive 04

Global Go-to-Market Strategies

Planning to take your first steps outside of your home market?

Global Go-to-Market Strategies

axxessive is a strategic Go-to-Market partner providing emerging biotechs with the knowledge required to plan and build presence in international markets. We determine an asset’s potential value, the key market launch sequencing, the P&L planning with FTE and investment requirements in a world with MFN, resulting in board-ready “Go-to-Market” plans. axxessive is the strategic, subrosa the execution part.

42health 05

HCP Promotion Field Teams Deployment

Smarter Launches. Stronger Brands. Faster Impact.

HCP Promotion Field Teams Deployment

We help biotechs and biopharma launch new brands and strengthen mature ones through flexible field-based commercial, educational, and reimbursement teams. Powered by strategic insight and technology, and active across all major regions, we accelerate launch performance and unlock commercial potential. For small innovators, we offer a full-service commercialization. For larger companies, we provide deployment solutions that complement existing capabilities. We shorten launch timelines, flex resources, and remove operational burden so you can focus on maximizing brand impact.

42health 06

Remote Sales & Customer Care Teams

Expand Your Commercial Reach

Remote Sales & Customer Care Teams

As access to HCPs is more challenging than ever, we develop the right engagement strategy and manage remote medical, sales & customer service teams that accelerate your growth. Our virtual MSL & KAM teams are trained for high performance. Whether you intend to reach “out-of-reach” HCPs in a Rare Disease indication, increase disease awareness, identify new patients, boost frequency, introduce a pre-launch campaign, connect with patient support & adherence programs or just to scale and speed-up, we are the right HCP engagement partner for you.

42health 07

Patient Support, Adherence Programs

Adherence Programs That Deliver Impact

Patient Support, Adherence Programs

42health designs, tailors and manages patient support & adherence programs, giving patients structured, hands-on support that addresses the challenges of day-to-day therapy use. We combine clear omnichannel education, guided onboarding, and continuous follow-up to help patients understand their medication, manage side effects, and stay engaged throughout the entire treatment journey. In Europe we are able to provide clinical services in the home environment. This sustained, real-world support stabilizes adherence, reduces drop-offs, and measurably improves long-term outcomes.

subrosa Capital 08

Licensing, Funds and M&A

Partnering, Capital & M&A

Licensing, Funds and M&A

subrosa Alliances acts as a hands-on value creation partner, selecting and rigorously assessing the right distribution, licensing (in & out) and co-development partners — specialized in the needs of Rare Disease and specialized biotechs. subrosa Capital helps you to identify the right investors — those aligned with your science, your timelines, and your long-term strategy — and guides you through a structured fundraising or grant application process. We identify, evaluate, and execute M&A transactions that strengthen your portfolio, expand your capabilities, accelerate growth or provide you an exit via selling assets or going for IPO.

explore Capital
Harvey & Nagl 09

Executive Search & Recruitment

Decades of Access to Top-Tier, Right Talent

Executive Search & Recruitment

subrosa Health’s experts on the ground in 29 offices across 21 countries delivered 3,600+ talents in 45 markets through intensive relationships to clinical, medical, and commercial profiles for orphans & biopharma — making impact from day one: permanent, ad interim (“xperiods”) or contracted. Harvey & Nagl’s executive search recruiters enjoy an outstanding market reputation, having fast-track access to the right leaders who make an impact from day one! (Harvey & Nagl Health-Intl., Harvey & Nagl Concord-US). We are recognized for our decades-deep relationships with the right individuals — and the ability to secure their commitment to your organization.

Trusted by leading life-science companies worldwide

AbbottAbbVieAbdiAbnobaAccordActelionActoBioAdvanzAdverum BioAegleaAgendiaAgiosAidianAimmuneAkceaAlbireoAlexionAlimeraAllerganAlmirallAlnylamAmarinAmgenAmicusAmrytAmylyxAngeliniAntaresApellisApontisArenaArgenxArmoArvelleAscendisAspenAstellasAstraZenecaAutolusAuxiliumAviaAvidityAzur PharmaB.BraunBasileaBausch & LombBavarian NordicBaxaltaBaxterBayerBeamBeiersdorfBeiGeneBeOneBesinsBIALBioCrystBiogenBiomarinBiometBioNTechBioprojetBiovailBluebird bioBlueprintBMSBoehringer IngelheimBoironBoston ScientificCamarusCarl ZeissCephalonChiesiChugaiClovisColgateCrineticsCSLcurrentzzCytokineticsDaiichi-SankyoDanoneDecipheraDenaliDiurnalDompeDr. FalkEisaiEsteveEUSAExact SciencesFerrerFerringFreseniusFujisawaGalapagosGaldermaGE HealthcareGedeon RichterGentiliGileadGrifolsGrünenthalGSKGTx Inc.Guardant HealthGW pharmaceuticalsHAL AllergieHaleonHalozymeHexalHorizonIdorsiaIncyteInterceptIntrexonIpsenItalfarmacoITF PharmaITMJ&JKaro PharmaKiadisKiteKlingeKyowa KirinLeo PharmaLigandLillyLindeLohmann & RauscherLundbeckLupinLyrixLyvyenLórealMadrigalMallinckrodtMead JohnsonMedacMediceMedImmuneMedtronicMenariniMerck SeronoMereoMerzMetrioPharmMiratiMirumMithraMSDMundipharmaMylanMyriadMölnlyckeNeopharmedNestléNikonNiproNordic PharmaNorgineNovartisNovavaxNovo NordiskNovocureOlympusOncoBetaOncopeptidesOnoOrionOrphalanOtsukaOvivaP&GPaul HartmannPfizerPharma&PharmacosmosPhytogenPierre FabrePiramalPortolaPrecigenProthenaQLTReckittRecodartiRegeneronResMedRevolution MedicinesRhythmRocheSageSalixSandozSanofiSantenSareptaScholar RockSeagenSenturiSeqirusServierShireSiemens HealthineersSmith & NephewSOBISpringsworksStebaStemlineStragenStridesStrykerSunovionTakedaTDSTenxTesaroTetrisTevaTherabelThermo FisherThromboGenicsTiberTorrentUS SurgicalUCBUnileverUriachValeantValnevaVernalisVertexViatrisVicuronViforViiVVygonYamanouchiZambonZogenixAbbottAbbVieAbdiAbnobaAccordActelionActoBioAdvanzAdverum BioAegleaAgendiaAgiosAidianAimmuneAkceaAlbireoAlexionAlimeraAllerganAlmirallAlnylamAmarinAmgenAmicusAmrytAmylyxAngeliniAntaresApellisApontisArenaArgenxArmoArvelleAscendisAspenAstellasAstraZenecaAutolusAuxiliumAviaAvidityAzur PharmaB.BraunBasileaBausch & LombBavarian NordicBaxaltaBaxterBayerBeamBeiersdorfBeiGeneBeOneBesinsBIALBioCrystBiogenBiomarinBiometBioNTechBioprojetBiovailBluebird bioBlueprintBMSBoehringer IngelheimBoironBoston ScientificCamarusCarl ZeissCephalonChiesiChugaiClovisColgateCrineticsCSLcurrentzzCytokineticsDaiichi-SankyoDanoneDecipheraDenaliDiurnalDompeDr. FalkEisaiEsteveEUSAExact SciencesFerrerFerringFreseniusFujisawaGalapagosGaldermaGE HealthcareGedeon RichterGentiliGileadGrifolsGrünenthalGSKGTx Inc.Guardant HealthGW pharmaceuticalsHAL AllergieHaleonHalozymeHexalHorizonIdorsiaIncyteInterceptIntrexonIpsenItalfarmacoITF PharmaITMJ&JKaro PharmaKiadisKiteKlingeKyowa KirinLeo PharmaLigandLillyLindeLohmann & RauscherLundbeckLupinLyrixLyvyenLórealMadrigalMallinckrodtMead JohnsonMedacMediceMedImmuneMedtronicMenariniMerck SeronoMereoMerzMetrioPharmMiratiMirumMithraMSDMundipharmaMylanMyriadMölnlyckeNeopharmedNestléNikonNiproNordic PharmaNorgineNovartisNovavaxNovo NordiskNovocureOlympusOncoBetaOncopeptidesOnoOrionOrphalanOtsukaOvivaP&GPaul HartmannPfizerPharma&PharmacosmosPhytogenPierre FabrePiramalPortolaPrecigenProthenaQLTReckittRecodartiRegeneronResMedRevolution MedicinesRhythmRocheSageSalixSandozSanofiSantenSareptaScholar RockSeagenSenturiSeqirusServierShireSiemens HealthineersSmith & NephewSOBISpringsworksStebaStemlineStragenStridesStrykerSunovionTakedaTDSTenxTesaroTetrisTevaTherabelThermo FisherThromboGenicsTiberTorrentUS SurgicalUCBUnileverUriachValeantValnevaVernalisVertexViatrisVicuronViforViiVVygonYamanouchiZambonZogenix
Commercial Engagement

Commercial Engagements embedded in subrosa’s 360° Health & Capital platform

Acceleration through fast ACCESS to…

Rare Diseases Market Size Validation

Massive Gap Between Assumed and Real Rare Disease Prevalence

Understanding the true prevalence and incidence of diseases is fundamental to healthcare planning. Accurate prevalence data also underpin orphan-drug designation and inform policy makers as they allocate resources for biomedical research.

Orphanet demonstrated the strong predictive value of literature volume on the estimation of prevalence in rare diseases, the rarest a disease is, the less publications are available, the less predictable is the prevalence and the less amount of patients a study is susceptible to include, the higher is the chance of negative studies.

At the same time, nearly all patient identification studies and also a new meta analyses show a dramatic gap between assumed and real patient numbers: active, systematic screenings of at risk populations uncover a “geometric mean range” of roughly 12 to 24 times more diagnoses than passive (based on published evidence and KOL assumptions) ascertainment. The “under-estimation-factors” go from 1.7x to >1500x (ATTRv), the summary of Fabry studies show 57x. Consequently, prevalence ends up being always severely understated.

Too low amount of literature is one reason for the remarkable under-estimation of the prevalence, incidence or market size of nearly any rare disease in the status of “unmet need”. A further reason could be that especially the Early (young) Patients are under-represented mainly due to the diagnostic delay and therefore the lack of knowledge about the early manifestation symptoms.

This is exactly where subrosa adds value.

subrosa OmicsAI can evaluate, validate, and publish the real prevalence, incidence, and market size for nearly any genetically driven Rare Disease (≈73% of all RD indications) — a critical capability in areas of unmet need. The earlier our active early patient identification programs begin the better, best before or in parallel with CRO activities well before launch to ensure more eligible patients for time-sensitive trials and to generate realistic epidemiological data for orphan designation, health-economic models, and even capital-market communication. Imagine being able to reference a peer-reviewed publication demonstrating a market size ten times larger than expected.

And ultimately, early patient identification does more than improve models — it ensures that patients who already qualify for treatment receive it before irreversible organ damage occurs.

Insights, knowledge & experience matter. Every patient counts

Explore OmicsAI Speak with a Rare Disease expert How Rare is it?
Patient Identification (Post-Launch)

Identifying Early Rare Disease Patients Through
“Real-Patient-Evidence” Data

Many patient identification strategies rely on AI-generated probabilities, digital signals, or estimated cohorts. But a probability is not a real patient. We have a fundamentally different approach.

subrosa OmicsAI’s clinical patient identification programs are built on our proprietary global repositories of rare disease patients — one of the world’s largest — genetically confirmed, sourced from real clinical diagnostics, not from algorithmic predictions.

Our rare disease genetics scientists from offices across US, Europe, China, APAC, CIS, GCC and LATAM run the clinical studies aligned with your medical team. By recruiting new cohorts in a unique way, patients are detected where no other organization can recruit them, years earlier than today’s standards. Hitting a precisely calculated success rate. Not estimated, data-driven calculated. Proven in more than 40 worldwide published programs.

Identification without access to patients is only one slide in a deck. Holistic patient access by subrosa accelerates outcomes. We keep both physicians & patients engaged across the full clinical journey through sustained communication. Ensuring that patients receive treatment & stay adherent — even in markets without product authorization via Early Access, Compassionate Use and Named Patient Programs.

Illuminating the unseen — no rare disease patient should be left behind

Explore OmicsAI Get in Touch
Commercial Engagement

Finding Rare Disease Patients Additionally Through

Clinical Patient Identification Programs

Omnichannel Communication

42health’s field, remote, or hybrid teams find patients through communication with “out-of-reach” HCPs, educating them on disease awareness for non-genetic (27%) or genetic-based (73%) Rare Disease indications.

Face Recognition

In addition to the clinical symptoms and recorded images of subrosa OmicsAI’s patient database, we are developing a global dataset of Rare Disease facial characteristics using images crowdsourced from clinicians, patients, patient organizations, labs, researchers, and screening programs. This real-world data — mapped to HPO terms — is not a big breakthrough in patient identification but will bring the occasional add-on patient and may speed up our clinical programs.

KOL-Network (Like CROs)

We find patient populations through our intensive global Rare Disease KOL network in the “Centers of Excellence” and collaboration with Patient Advocacy Organizations and databases of authorities.

Patient Organizations / Authorities

Collaboration with Patient Advocacy Organizations and the databases of authorities.

HCP Promotion Field Teams – Full Service & Deployed

Scientific Dialogue for Smarter Launches Stronger Brands Faster Impact Scalable

We support both emerging biotechs and global biopharmaceutical companies in launching new brands and elevating the performance of non-core or mature brands. Our model enhances the efficiency and flexibility of traditional sales structures by integrating field-based roles that educate the market and promote therapies where they matter most.

subrosa designs, builds, and manages high-performing sales, educational, and reimbursement teams that consistently deliver superior ROI. We provide a full spectrum of field-facing capabilities tailored to your brand and market needs:

Key Account Manager Hospital Representative Sales Representative Educational Representatives Field Reimbursement Managers (FRM) Managed Care Liaisons (MCL) Government Affairs Expert (GAE) Genetic Counselor (GC)

Our customized solutions are powered by strategic insight, advanced technology, and authentic human engagement. With operational reach across North America, Europe, Asia, CIS, GCC, and LATAM, we accelerate global launch performance and unlock full commercial potential.

For small, innovative biopharma companies with limited internal resources, we offer end-to-end commercialization through our Full-Service Commercialization model. For larger organizations seeking to augment existing capabilities, we provide Deployment Solutions — a strategic blend of proprietary services and purpose-built infrastructure.

We shorten launch-readiness timelines, flex and redeploy resources, and take on operational complexity so you can stay focused on maximizing your brand’s performance.

Why subrosa? Our scientific and operational capability to navigate geographic and profile requirements at speed, and to design and execute deployed programs of any size. This includes strategy, stakeholder mapping, high-quality “plug-in & play” team recruitment, training, field execution, data analytics, and performance management across therapeutic areas and regions — fully aligned with compliance.

Commercial Engagements

Commercial & Reimbursement Teams

Expertise and insights to deliver the right information to the right people at the right time to optimize patient care.

Managed Care Liaison

MCL
  • Value proposition to payers and insurance companies
  • Experts on pharmacoeconomics and clinical data
  • Communicate insights to/from the field
  • Key contact for MCO, government programs, employers, hospital systems

Government Affairs Expert

GAE
  • Represent the company in front of politicians, authorities, policy makers, payers
  • Educate on clinical & scientific and pharmacoeconomic data
  • Influence company strategy by bringing insights to/from the field

Educational Representative

  • Non-promotional
  • Therapeutic area updates
  • Disease state awareness
  • Clinical insights
  • Treatment landscape shifts

Field Reimbursement Manager

FRM
  • Acts as a liaison between providers, payers, patient hubs, and internal pharma teams
  • Helping providers to secure reimbursement
  • Educates HCPs on payer policies & documentation
  • Support admin & shortens time to therapy

Nurse Educators

NE
  • Educate local HCPs in community
  • Hands-on training for products (dosage, injectables)
  • Train the Trainer
  • Can interact with patients directly

Genetic Counselor

  • Educate HCPs on Personalized Medicine, NGS
  • Implement best diagnostic testing strategy
  • Genetic test interpretation and analysis
  • Genetic counseling via telemedicine (pre- or post-test)
Commercial Engagements

Options for Global Commercial Partnerships

operating models for dedicated or syndicated medical & commercial teams, or partnering through distribution & out-licensing contracts

Increasing subrosa involvement
1

Direct to Headcount — Managed by You

→ executive search & recruit

subrosa provides active candidate sourcing aligned to your needs; full management of assessment process of executive search of HQ VPs and recruitment of MSL/KAM F2F, remote omnichannel or hybrid teams; provision of xperiods, interim executives to secure seamless management coverage & RPO-services.

2

Direct to HC, Managed by You, Support by subrosa

→ executive search, recruit & HR-Services

Executive search of HQ VPs and recruitment of MSL/KAM F2F, remote omnichannel or hybrid teams; recruited candidates employed by you. subrosa provides needed HR services: RPO, local employment contracts, payroll management, SOPs, IT, compliance-CRM, fleet, mobile phones, travel expenses, backoffice, training.

3

Dedicated Temps — Managed by You

→ executive search, recruit & employ

subrosa provides field resources (incl. all HR-services) to be managed by you; recruitment & deployment of FTEs, field teams by subrosa; first line management by you; optional provision of integrated disease awareness, patient finding, adherence, patient support & omnichannel programs.

4

Dedicated Temps — Managed by subrosa

→ recruit, train, employ & manage

subrosa provides and fully manages clinical, medical & commercial field teams; recruitment & deployment of FTEs and first-line managers by subrosa; training, performance management & development; leading technique and stakeholder insights (KOLs, HCPs, etc.).

5

Dedicated Full Service — Managed by subrosa

→ recruit, train, employ, manage & lead

subrosa recruits, deploys and fully manages field resources incl. training, performance management & development; subrosa project director assigned to oversee and liaise with you, responsible for performance, no need for local resources; segmentation, profiling, team sizing, territory design.

6

Syndicated Full Service — Managed by subrosa

→ manage & lead subrosa-own team

subrosa provides a non-competing drug position in a medical & commercial syndicated MSL or KAM team, only in Europe; subrosa business unit director is responsible for performance, no need for local resources; cost-sharing model.

7

Managed by Commercialization Partners — Assessments & Alliance Management

→ managed by commercialization partners

subrosa Alliances selects your partner for in- & out-licencing, co-financing and distribution agreements, cost-sharing models in your non-core countries; intensive finance, business planning and M&A consulting for EMEA.

Remote Medical, Sales & Customer Care Teams

Extend Your Commercial Reach with Our HCP Engagement Teams

In an environment where access to HCPs, pharmacists, and other healthcare stakeholders is more challenging than ever, biopharma requires engagement strategies that are adaptable, reliable, and deeply attuned to both brand priorities and customer needs.

Our strength is in developing the right and engagement strategy according to your needs and manage remote medical, sales and customer service teams, that accelerate your growth without compromising the quality your customers rely on.

Our remote teams are trained for high performance

Our remote MSL and Rep teams from the 42health Dialogue Center are far more than call-center agents. They are trained and developed to the same standards as their field colleagues—skilled in complex scientific conversations, adaptable to HCP schedules, and empowered to build long-term, omnichannel relationships that increase profitability and share of voice. They’re supported by continuous coaching, real-time insights, and a culture built for excellence.

Remote Medical, Sales & Customer Care Teams

Where Are You in Your Commercialization Journey?

What we can do.

Let’s design a smart, efficient, and high-impact virtual engagement journey together — and build a tailored team aligned with customer needs, market realities, and your brand goals, whether you want to:

  • reach the out-of-reach HCPs in addition to small MSL and KAM teams in case of, e.g., a Rare Disease indication
  • increase disease awareness and/or identify new patient populations
  • boost frequency towards key HCPs in a specialized, e.g., oncology sales force
  • introduce a pre-launch campaign, fixing also appointments for customers’ MSLs or KAMs
  • connect with patient support & adherence programs intelligently
  • or just scale and speed up (and much more)

Why 42health as your remote HCP engagement partner?

Over a decade of experience in designing, building, leading, and developing high-performance teams — embedded as a true extension of your field force — helping your brands build value and protect market share with flexible operating models. We would like to be a part of your success story, always keeping our promises and avoiding promises we might not be able to keep.

CAMBRIDGE MIAMI ZUG MUNICH MANNHEIM LUNENBURG VIENNA LONDON UXBRIDGE BARI MADRID AMSTERDAM STOCKHOLM VILNIUS WARSAW LJUBLJANA TBILISI DUBAI JERUSALEM WUXI HAINAN CHENNAI SINGAPORE MEXICO CITY SAO PAULO BUENOS AIRES

Built for speed

We don’t promise what we might not be able to keep.

Get in Touch #teamsubrosa